Looking for information on Immutep and its Lag-3 technology?

Get in touch!

 

Thank you for your interest in Immutep and the cancer and autoimmune treatments made possible by our Lag-3 technology. For media requests, or to contact the Immutep team regarding partnerships, email enquiries@immutep.com and a member of our support team will direct your inquiry.

Please add 3 and 6.

* Required

USA Investor Relations

Chris Basta
VP, Investor Relations and Corporate Communications
Ph: +1 (631) 318-4000

 

Australian Investor Relations

Catherine Strong
Citadel-Magnus
Ph: +61 (0) 406 759 268

Immutep Limited
Sydney Office

Ph: +61 2 8315 7003
Fax: +61 2 8569 1880

Level 32, Suite 32.07 Australia Square
264 George Street, Sydney
NSW 2000, Australia

Immutep S.A.S.
Paris Office

Ph: +33 (0) 160 123 250

Parc Les Algorithmes 
Bâtiment 7- Le Pythagore
Route de l’Orme - RD128
91190 SAINT-AUBIN
France

Immutep GmbH
Berlin Office

Ph: + 49 30 88716843

Glinkastr. 28
10117 Berlin
Germany

Immutep Australia Pty Ltd

GPO Box 437
SYDNEY NSW 2001
Australia

E-Mail List

You may automatically receive Electronic Communications by e-mail, please sign up here.

Shareholder Services
Boardroom

The share registry may be accessed by clicking here.

Ph: +61 2 9290 9600
Fax: +61 2 9279 0664

www.boardroomlimited.com.au

Share Registry
Level 8, 210 George Street
Sydney NSW 2000

Postal Address:
GPO Box 3993
Sydney NSW 2001